Trial · NCT03320941
Outcomes19
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage Change From Baseline in Body Weight at Week 12 | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study drug | Percent Change | NUMBER |
| SECONDARY | Responder Rates According to Percentage Decrease in Body Weight From Baseline to Week 12 | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study drug | Percentage of Participants | NUMBER |
| SECONDARY | Percentage Change From Baseline in Body Weight at Week 12 in Dysglycemic Participants and Participants With Type 2 Diabetes Mellitus (T2DM) | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | percentage change | NUMBER |
| SECONDARY | Change From Baseline at Week 12 on Waist Circumference at Umbilical Level | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | cm | MEAN |
| SECONDARY | Percentage Change From Baseline at Week 12 on Hemoglobin A1c (HbA1c) | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | Percentage | MEAN |
| SECONDARY | Change From Baseline at Week 12 on Fasting Plasma Glucose (FPG) | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | mmol/L | MEAN |
| SECONDARY | Change From Baseline at Week 12 on Systolic Blood Pressure (SBP) | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | mmHg | MEAN |
| SECONDARY | Change From Baseline at Week 12 on Diastolic Blood Pressure (DBP) | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | mmHg | MEAN |
| SECONDARY | Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Triglycerides (TG) | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | Percentage | MEAN |
| SECONDARY | Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Total Cholesterol | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | Percentage | MEAN |
| SECONDARY | Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - High Density Lipoprotein (HDL) | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | Percentage | MEAN |
| SECONDARY | Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Low Density Lipoprotein (LDL) | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | Percentage | MEAN |
| SECONDARY | Percent Change From Baseline at Week 12 on High Sensitive C-reactive Protein (hsCRP) | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | Percentage | MEAN |
| SECONDARY | Change From Baseline in Uric Acid at Week 12 | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | μmol/L | MEAN |
| SECONDARY | Change From Baseline on Urine Albumin at Week 12 | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | x 10^4 mmol/L | MEAN |
| SECONDARY | Change From Baseline on Urine Albumin to Creatinine Ratio at Week 12 | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | mg/mmol | MEAN |
| SECONDARY | Percent Change From Baseline on Visceral Fat Area (VFA) at Week 12 | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | Percent | MEAN |
| SECONDARY | Percent Change From Baseline on Subcutaneous Fat Area (SFA) at Week 12 | Baseline, Week 12 | Full analysis set (FAS) - includes all 126 randomized participants that took at least one dose of study (two subgroups Dysglycemic had total of 57 patients and T2DM had total of 69 patients) to equal 126 | Percentage | MEAN |
| SECONDARY | Pharmacokinetics - Plasma Trough Concentrations of LIK066 | Week 12 | Safety set (SAF): the SAF includes all participants who received at least one dose of study medication. | ng/mL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03320941/outcomes